Research Letters
The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus

https://doi.org/10.1016/j.cgh.2022.02.056Get rights and content

First page preview

First page preview
Click to open first page preview

References (9)

  • J. Choi

    JAMA Oncol

    (2019)
  • S.U. Kim

    J Hepatol

    (2019)
  • M.C. Elze

    J Am Coll Cardiol

    (2017)
  • S.W. Lee

    Gut

    (2020)
There are more references available in the full text version of this article.

Conflicts of interest The authors disclose no conflicts.

Funding This project was supported in part by Gilead Sciences (IN-US-174-5740), and the facilities and resources of the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413), the Michael E. DeBakey Veterans Affairs Medical Center, and the Texas Medical Center Digestive Diseases Center (National Institute of Diabetes and Digestive and Kidney Diseases P30 DK 56338-10/15), Houston, Texas. Dr. Kim was supported by the National Institute of Diabetes and Digestive and Kidney Diseases T32 grant (DK083266). The views expressed in this article are those of the authors and do not necessarily represent the views of the funding institutions.

View full text